The U.S. Food and Drug Administration (FDA) has approved Journavx (suzetrigine), a non-opioid medication for moderate to severe acute pain. 1 This approval expands treatment options for providers who want to reduce opioid exposure while ensuring effective pain relief for patients.
For providers, suzetrigine offers a new multimodal pain management tool, particularly for polydrug patients or those at risk for opioid misuse.2
What Does This Mean for Your Practice?
Providers managing postoperative pain, acute injuries, or opioid-sensitive patients now have a new treatment option that:
- Works peripherally – Suzetrigine blocks pain signals at the nerve level, rather than targeting opioid receptors 3
- May reduce opioid reliance – Can be prescribed as an alternative to traditional opioid-based pain regimens 1
- Fits within multimodal pain strategies – Works alongside NSAIDs, acetaminophen, and regional anesthesia 2
While opioids still have a role in acute pain management, having another non-opioid choice allows providers to better personalize pain relief strategies.1
Clinical Insights: How Effective Is Suzetrigine?
The FDA based its approval on two randomized, controlled clinical trials evaluating post-surgical pain management after bunionectomy and abdominoplasty.
- Patients receiving suzetrigine reported significantly lower pain scores through 48 hours after starting treatment compared to those on placebo 2
- Common side effects included itching, muscle spasms, rash, and elevated creatine kinase levels 1
Key Considerations for Prescribing
- Studied for postoperative pain management 1
- Not a full opioid replacement: Some patients may still require opioids for breakthrough pain, while suzetrigine may provide a safer starting point 3
- Monitor for side effects: Though well-tolerated in trials, providers should watch for muscle-related effects and skin reactions 1
axialHealthcare: Supporting Smarter Pain Care
At axialHealthcare, we help providers navigate evidence-based pain management strategies that balance effective pain relief with opioid risk mitigation. The approval of suzetrigine is an important step toward expanding safer treatment options, and we remain committed to helping providers integrate non-opioid alternatives into patient care when clinically appropriate.
Citations
- S. Food and Drug Administration (FDA). (2024). FDA approves novel non-opioid treatment for moderate to severe acute pain. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain
- Vertex Pharmaceuticals. (2024). Clinical trial results of suzetrigine for postoperative pain management. Retrieved from https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-results-phase-2-study-suzetrigine-treatment
- (2024). Mechanism of action and clinical efficacy of suzetrigine. Retrieved from https://pubmed.ncbi.nlm.nih.gov/39775738